Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) ROCE % : -72.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ginkgo Bioworks Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -72.10%.

Ginkgo Bioworks Holdings ROCE % Historical Data

The historical data trend for Ginkgo Bioworks Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings ROCE % Chart

Ginkgo Bioworks Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-20.34

-144.65

-98.61

-46.17

Ginkgo Bioworks Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-27.86	-37.59	-33.83	-38.16	-72.10

Ginkgo Bioworks Holdings ROCE % Calculation

Ginkgo Bioworks Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-892.847	/	( ( (2539.321 - 172.962)	+	(1665.342 - 163.86) )	/ 2 )
	=	-892.847	/	( (2366.359	+	1501.482)	/ 2 )
	=	-892.847	/	1933.9205
	=	-46.17 %

Ginkgo Bioworks Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1211.072	/	( ( (2026.392 - 168.462)	+	(1665.342 - 163.86) )	/ 2 )
	=	-1211.072	/	( ( 1857.93	+	1501.482 )	/ 2 )
	=	-1211.072	/	1679.706
	=	-72.10 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Ginkgo Bioworks Holdings (NYSE:DNA.WS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ginkgo Bioworks Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA.WS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DNA:USA DNA:Mexico

Address

27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210

Website

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.